Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96573267 | 9657326 | 7 | F | 20160822 | 20160908 | 20131030 | 20160912 | EXP | US-GLAXOSMITHKLINE-A1047429A | GLAXOSMITHKLINE | 29.97 | YR | F | Y | 0.00000 | 20160912 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96573267 | 9657326 | 1 | PS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | 28.5 NG/KG/MIN CONTINUOUSLY (CONCENTRATION 45,000 NG/ML; 1.5 MG VIAL STRENGTH) | U | P828 | 20444 | 28.5 | DF | POWDER FOR INFUSION | |||||
| 96573267 | 9657326 | 2 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | 48.5 NG/KG/MIN, 60,000 NG/ML, 76 ML/DAY, 1.5 MG CO | U | T794 | 20444 | 48.5 | DF | POWDER FOR INFUSION | |||||
| 96573267 | 9657326 | 3 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | 55 NG/KG/MIN, CO | U | Z606 | 20444 | 55 | DF | POWDER FOR INFUSION | |||||
| 96573267 | 9657326 | 4 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | 55 NG/KG/MIN, CO | U | Z880 | 20444 | 55 | DF | POWDER FOR INFUSION | |||||
| 96573267 | 9657326 | 5 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | U | C764454 | 0 | SOLUTION FOR INJECTION | |||||||||
| 96573267 | 9657326 | 6 | C | WARFARIN POTASSIUM | WARFARIN POTASSIUM | 1 | U | 0 | |||||||||||
| 96573267 | 9657326 | 7 | C | FUROSEMIDE. | FUROSEMIDE | 1 | U | 0 | |||||||||||
| 96573267 | 9657326 | 8 | C | REVATIO | SILDENAFIL CITRATE | 1 | U | 0 | |||||||||||
| 96573267 | 9657326 | 9 | C | WARFARIN | WARFARIN | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 96573267 | 9657326 | 1 | Pulmonary arterial hypertension |
| 96573267 | 9657326 | 5 | Pulmonary arterial hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 96573267 | 9657326 | HO |
| 96573267 | 9657326 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 96573267 | 9657326 | Blood sodium increased | |
| 96573267 | 9657326 | Catheter site infection | |
| 96573267 | 9657326 | Cold sweat | |
| 96573267 | 9657326 | Device infusion issue | |
| 96573267 | 9657326 | Feeling cold | |
| 96573267 | 9657326 | Fluid overload | |
| 96573267 | 9657326 | Infection | |
| 96573267 | 9657326 | Oedema | |
| 96573267 | 9657326 | Pallor | |
| 96573267 | 9657326 | Transplant |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 96573267 | 9657326 | 1 | 20101228 | 0 | ||
| 96573267 | 9657326 | 4 | 20101220 | 0 |